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Key questions
What is already known?
 ► While an extensive array of evidence about access 
to malaria care insecticide- treated bed nets, diag-
nostics and treatments, as well as quality of malaria 
diagnostic tests and drugs are available, we know 
much less about the quality of malaria care provision 
and how quality of malaria care compares across 
low- incomeand middle- income countries (LMICs).
What are the new findings?
 ► Quality of malaria care remains poor in many LMICs 
despite increasing access to malaria care tests and 
treatment drugs.
 ► Quality of care varies across the treatment cascade 
with febrile children often not receiving blood tests, 
resulting to improper treatment of malaria; thus, 
treatments are often prescribed regardless of ma-
laria test results.
 ► Poor quality of malaria care also varies widely by 
regions with capital cities not necessarily providing 
better quality of malaria care than others.
What do the new findings imply?
 ► Our findings suggest that the quality of malaria for 
children under five in many LMICs is quite low and 
that quality of care varies by malaria treatment cas-
cade and regions.
 ► There is both undertreatment and overtreatment, re-
gardless of malaria test results, requiring the need to 
strengthen future quality improvement strategies to 
ensure prompt and correct malaria testing and treat-
ment across countries.
AbsTrACT
Introduction Even with accessible and effective 
diagnostic tests and treatment, malaria remains a leading 
cause of death among children under five. Malaria case 
management requires prompt diagnosis and correct 
treatment but the degree to which this happens in low- 
income and middle- income countries (LMICs) remains 
largely unknown.
Methods Cross- sectional study of 132 566 children under 
five, of which 25% reported fever in the last 2 weeks from 
2006 to 2017 using the latest Malaria Indicators Survey 
data across 25 malaria- endemic countries. We calculated 
the per cent of patient encounters of febrile children under 
five that received poor quality of care (no blood testing, 
less or more than two antimalarial drugs and delayed 
treatment provision) across each treatment cascade and 
region.
results Across the study countries, 48 316 (58%) 
of patient encounters of febrile children under five 
received poor quality of care for suspected malaria. 
When comparing by treatment cascade, 62% of cases 
were not blood tested despite reporting fever in the last 
2 weeks, 82% did not receive any antimalarial drug, 17% 
received one drug and 72% received treatment more than 
24 hours after onset of fever. Of the four countries where 
we had more detailed malaria testing data, we found that 
35% of patients were incorrectly managed (26% were 
undertreated, while 9% were overtreated). Poor malaria 
care quality varies widely within and between countries.
Conclusion Quality of malaria care remains poor and 
varies widely in endemic LMICs. Treatments are often 
prescribed regardless of malaria test results, suggesting 
that presumptive diagnosis is still commonly practiced 
among cases of suspected malaria, rather than the WHO 
recommendation of ‘test and treat’. To reach the 2030 
global malaria goal of reducing mortality rates by at least 
90%, focussing on improving the quality of malaria care is 
needed.
InTroduCTIon
Malaria represents one of the leading 
burdens of illness among children, ranking 
among the major health and develop-
ment challenges for many low- income and 
middle- income countries (LMICs). Overall, 
there were an estimated 219 million malaria 
cases in 2017 across 91 countries, a number 
that is actually increasing (an estimated 5% 
increase from 2016).1 More than 60% of all 
malaria deaths occur in children under the 
age of five and despite progress in this popu-
lation, malaria remains a major killer, with 
about 300 000 children dying every year.2 To 
reduce malaria deaths, early diagnosis and 
prompt, effective treatment is essential,1 and 
improved access to care through universal 
coverage is considered critical. However, 
there is some data to suggest that inadequate 
testing of febrile children and generally poor 
quality of malaria care, defined in this study 
as providing malaria drugs without blood 
testing for malaria, receiving more than the 
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recommended antimalarial drugs, or receiving delayed 
malaria treatment, may be a substantial hindrance to 
reducing malaria mortality. Given these concerns, esti-
mating poor malaria care quality is particularly impor-
tant, but recent studies3 were not able to quantify this. 
Without knowing how rampant poor quality of care is, 
the stated WHO global target of reducing mortality by 
90% by 2030 remains unachievable.2
The degree to which poor quality care is a barrier 
to reducing malaria deaths is largely unknown, partly 
because we know very little about the quality of malaria 
care in LMICs (online supplementary appendix 1). 
There have been a few studies examining these issues4–10 
though they are limited by the lack of comparable quality 
of care data across countries. A few more comprehensive 
studies of quality of care in LMICs have excluded malaria 
in their evaluations.11 12 Despite its central importance, 
we have a surprisingly incomplete picture of the quality 
of malaria care, how it varies across settings, and where 
on the diagnosis and treatment cascade the failures 
occur. This kind of information is critical to help policy-
makers better decide both how much to focus on quality 
and where in the clinical process that attention should 
be emphasised. Empirical evidence here would be very 
helpful.
New and comparable data on malaria care testing and 
treatment across LMICs were recently collected and made 
available through the Roll Back Malaria programme. 
Using their latest available data for malaria endemic 
LMICs, we sought to answer three questions: First, what is 
the quality of malaria care in 25 malaria- endemic LMICs? 
Second, what is the distribution of that poor quality of 
care across the treatment cascade? And, finally, how does 
the poor quality of care vary across the regions of each 
study country?
MeTHods
We conducted a cross- sectional study in 25 malaria- 
endemic countries (Angola, Burkina Faso, Burundi, 
Cambodia, Cameroon, Ethiopia, Gambia, Ghana, 
Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, 
Namibia, Nigeria, Rwanda, Senegal, Sierra Leone, Swazi-
land, Tanzania, Togo, Uganda, Zambia and Zimbabwe) 
using the most recent malaria survey data from 2006 to 
2017.
study population and data sources
We gathered cross- sectional survey data on 132 566 
under- five children in 25 malaria- endemic LMICs (online 
supplementary appendix 2), of which children who 
were febrile in the last 2 weeks and who sought care for 
reported fever were selected to assess malaria care quality 
(online supplementary appendix 3). Data were obtained 
from the most recent Malaria Indicators Surveys (MIS) 
from 2006 to 2017, which are nationally- representative, 
population- based sample surveys collecting data on 
insecticide- treated nets, patterns of diagnostic testing 
and antimalarial use among malaria- endemic countries. 
The MIS sample was selected using a stratified two- stage 
cluster design.13 The first stage involved clusters with 
probability proportional to size from the list of enumera-
tion areas covered in the population and housing census. 
In the second stage, for all the selected enumeration 
areas, households were randomly selected using an equal 
probability systematic sampling. MIS include two types 
of data: women’s and biomarker questionnaires. The 
women’s questionnaire found in 25 countries was used 
to assess care seeking, diagnostic testing and access to 
prompt treatment with antimalarials for under- five chil-
dren with fever as reported by women interviewed. The 
biomarker questionnaire available in four of the 25 study 
countries confirms malaria using malaria rapid diagnostic 
tests (mRDTs) or blood smear test results. The biomarker 
data were used to reduce potential recall and misclassi-
fication bias on the diagnosis of malaria obtained from 
the women’s questionnaire. Bias due to missing data is 
unlikely to have affected our results substantially because 
our findings were relatively similar when we analysed only 
patients with complete data and when assessing quality of 
care using other outcome measures (Appendices 4 to 7: 
Sensitivity analyses).
Variables
Among febrile under- five children who sought care, we 
used variables that were relevant to the WHO recommen-
dations on malaria care, including whether or not they 
had their blood tested for fever, whether or not they had 
been treated for malaria with one antimalarial drug or 
more than three antimalarial drugs and whether or not 
they received malaria care within 24 hours from the onset 
of fever. It would have been ideal to determine timely 
care by examining whether or not they received malaria 
care within 24 hours from the time they sought care or 
when they first saw a healthcare provider. Unfortunately, 
existing data only provide time from the onset of fever. 
Responses were either yes or no based on mother’s recall 
of the treatment of their febrile child in the last 2 weeks.
Main outcome measure
Our unit of analysis is a patient encounter, which refers to 
any distinct interaction of a patient with a provider at any 
point of the treatment cascade. One patient may have 
more than one encounter, representing different types 
of care along the treatment cascade where the provider 
can follow WHO recommended care or not. Our primary 
outcome was guided by WHO- recommendations and was 
calculated as the proportion of patient encounters with 
poor quality defined as the number of times a patient 
interacted with a health provider and received care that 
did not follow the WHO recommendations for any of 
the three treatment cascades (malaria testing, malaria 
treatment provision and malaria treatment timeliness). 
Online supplementary appendix 3 details how poor 
malaria care quality is defined in this study.
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statistical analysis
First, we report summary statistics (number of under- 
five children, wealth and education) of the study 
countries corresponding to each survey year and 
then compared survey estimates to the estimates from 
country reports to examine sample representativeness. 
Second, we compared the percentages of febrile chil-
dren who sought care to those who did not seek any 
medical care. Third, limiting our analysis to febrile chil-
dren who sought medical care, we then calculated the 
percentage of poor malaria care quality overall and for 
each treatment cascade by calculating the total number 
of times the patient received inappropriate care out of 
all instances wherein a patient may have gone through a 
treatment cascade (malaria testing, treatment and time-
liness). For malaria testing, an encounter is considered 
of poor quality if no blood test through either mRDTs or 
blood smears were done before treatment.14 For malaria 
treatment provision, an encounter is considered to be 
poor quality if the child did not receive any antimalarial 
treatment (no treatment), received only one antimalarial 
drug (inadequate treatment)15 or three or more antima-
larial drugs (overtreatment). For malaria treatment time-
liness, an encounter is considered to be of poor quality if 
the patient is treated more than 24 hours from the onset 
of fever (delayed treatment). To calculate the overall 
burden of poor malaria care quality, patient encounters 
with poor malaria care quality were summed and divided 
by the total possible treatment cascades a patient may 
have gone through. We also conducted a secondary anal-
ysis calculating the proportion of cases that were under-
treated and overtreated using additional laboratory test 
results from four of the 25 study countries with available 
data. We also mapped the calculated percentages of 
patient encounters with problems on malaria care quality 
by regions of each study country. Since some countries 
did not have more recent data, we correlated poor quality 
of care with other population characteristics such as gross 
domestic product per capita, year of survey and per cent 
of febrile children out of total population.
We limited all our analyses to under- five children who 
reported fever in the last 2 weeks. We used the survey 
weights to make the sample representative of the country 
and eliminate the potential non- proportional allocation 
of the sample.16 The biomarker data available for four 
of the 25 countries, including repeating the analysis only 
for those who had complete data or who went through 
all the treatment cascades, were used for additional sensi-
tivity analyses (Appendices 5 to 7). All analyses were done 
in Stata V.15.1. Maps were created using ArcGIS V.10.6.1.
Patient and public involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for the design or implementation 
of the study. No patients were asked to advise on inter-
pretation or writing up of results. There are no plans to 
disseminate the results of the research to study partici-
pants or the relevant patient community.
role of the funding source
The authors received no specific funding for this work. All 
authors had full access to all the data in the study and had 
the final responsibility for the decision to submit for publi-
cation.
resulTs
Results are divided into two sections: (a) a data gap anal-
ysis on malaria care quality, and (b) estimation of poor 
malaria care quality using existing available and most 
complete data.
data gap analysis on malaria care quality
We found that despite existing nationally representa-
tive surveys specifically focussed on malaria such as the 
Malaria Indicators Survey, there are still limited data to 
quantify quality of malaria care by treatment cascade. 
Thus, malaria surveys still do not comprehensively 
capture malaria care quality. First, reasons for not seeking 
care were not provided by the survey, which could have 
been important information to improve access to malaria 
care. Second, data on blood testing were not available 
for four malaria- endemic countries (Cameroon, Ethi-
opia, Swaziland and Senegal). Similarly, only four of 
the 25 study countries had available data on malaria test 
results to confirm appropriate treatment route for febrile 
children under five. Third, data were based on moth-
er’s recall of the antimalarial drugs taken by their child 
instead of the actual doctor’s prescriptions; thus, this 
may not completely reflect the treatment process. Lastly, 
future surveys can follow children not only throughout 
the cascade, but also once the treatment is complete to 
know the consequences of the quality of malaria care 
treatment received by the child. Similarly, patient history 
is lacking in most surveys and should be made available 
since recurrence of malaria may impact how the malaria 
care treatment is provided by a healthcare worker. 
Considering these data gaps, our findings shown in the 
succeeding sections estimate malaria care quality where 
data are most complete and where reasonable assump-
tions can be made to provide the critical evidence on how 
poor malaria care quality is in the study countries.
Characteristics of sampled children under five and their 
households
Our survey sample totalled 132 566 children under five from 
each latest available survey from 2006 to 2017 (table 1). Of 
these children, a mean across countries of 23% belong to 
households in the lowest wealth index and a mean of 28% 
belong to households in the wealthiest index. Our sample 
had 5% more children belonging to the poorest and 6% 
more belonging to the wealthiest compared with country 
reported estimates. A mean of 16% of our survey sample 
lives in urban areas, compared with the 24% reported in 
the country estimates. Of the children’s mothers, a mean 
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Table 1 Survey characteristics and socioeconomic profile of under- five children and their households
Country Year
Number of 
under- five 
children
Proportion belonging to 
poorest wealth index Proportion urban
Proportion of mothers 
who attained primary 
education or less
Survey Survey
Country 
reports Survey
Country 
reports Survey
Country 
reports
Angola 2011 3025 24% 11% 12% 33% 90% 81%
Burkina Faso 2014 6324 21% 18% 16% 25% 92% 82%
Burundi 2012 3984 23% 20% 18% 21% 93% 84%
Cambodia 2005 3796 25% – 17% – 82% –
Cameroon* 2011 5286 23% 18% 16% 17% 69% 53%
Ethiopia* 2016 9696 24% 16% 14% 23% 93% 83%
Gambia* 2013 3640 21% 16% 17% 2% 73%   –
Ghana 2016 3034 22% 16% 18% 24% 47% 36%
Kenya 2015 3356 26% 16% 18% 27% 65% 54%
Liberia 2016 2611 23% 16% 16% 25% 65% 56%
Madagascar 2016 6832 25% 18% 16% 24% 74% 65%
Malawi 2017 3694 23% 19% 18% 23% 82% 77%
Mali 2015 7302 21% – 17% – 89% –
Mozambique* 2015 4843 23% 35% 14% 48% 84% –
Namibia* 2013 1945 25% – 14% – 31% –
Nigeria 2015 6161 21% 18% 19% 23% 63% 54%
Rwanda 2013 3018 23% 19% 17% 23% 90% 81%
Senegal 2009 13 884 23% 17% 16% 24% 92% 82%
Sierra Leone 2016 5720 22% 18% 16% 24% 75% 66%
Swaziland* 2007 2226 22% – 17% – 45% –
Tanzania* 2012 7054 23% 17% 16% 26% 92% 30%
Togo 2017 3271 23% 17% 18% 24% 73% 63%
Uganda 2015 4300 23% 18% 17% 25% 78% 69%
Zambia 2014 12 311 24% – 15% – 67% 63%
Zimbabwe 2015 5253 24% – 17% – 33% –
Total 132 566†       
Mean 23% 18% 16% 24% 73% 66%
Data source: Calculated data were from 2005 to 2017 Malaria Indicators Survey, Reported data were from the Country Reports. See online 
supplementary appendix.
*Only biomarkers data are available.
†Total number of under- five children was calculated using survey weights.
of 73% attained primary education or had no formal 
education, greater by 7% than the reported country esti-
mates. The difference between the survey and the country 
estimates was found to be insignificant (p>0.05); thus, our 
sample is nationally representative.
Care seeking among febrile children under five
Of the 132 566 children surveyed, a mean of 25% of chil-
dren reported fever in the last 2 weeks (figure 1a). Of 
these febrile children, a mean of 19% (n=6436) did not 
seek care for fever. The highest percentages of children 
who did not seek care for fever were in Ethiopia (53%, 
n=717), Burundi (36%, n=609) and Zimbabwe (35%, 
n=264). The lowest percentages of children who did not 
seek care for fever were in Uganda (5%, n=65), Ghana 
(6%, n=52) and Sierra Leone (8%, n=123).
burden of poor quality of malaria care
Overall, 58% of patient encounters (n=59 920) reported 
having poor malaria care quality (figure 1b). The highest 
percentages of patient encounters with poor quality were 
in Tanzania (69%, n=2925), Nigeria (66%, n=4320) and 
Mozambique (65%, n=1983). The lowest percentages 
were in Liberia (48%, n=1322), Sierra Leone (49%, 
n=2204) and Zambia (50%, n=3581). The estimated 
58% of patient encounters receiving poor malaria care 
quality reduced to 35% when considering only the four 
countries (Angola, Ghana, Nigeria and Senegal) that had 
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Figure 1 Care seeking behaviour and quality problems in malaria care among febrile children under five. (A) Percentage of 
cases of under- five children who did not seek care versus those that sought care. (B) Among those seeking care, number 
of patient encounters with problems on quality of malaria care. Note: There is no available information on blood testing in 
Cameroon, Ethiopia, Senegal and Swaziland. Inadequate treatment refers to the number of patient encounters wherein children 
were treated with one antimalarial drug, which does not include artemisinin or combination therapies. Red line = mean for all 
the study countries.
additional malaria laboratory test results (online supple-
mentary appendix 4). About 26% (n=1992) were due to 
undertreatment and 9% (n=952) were due to overtreat-
ment. Large percentages were still found even when 
using different estimation methods (Appendices 5 to 7: 
Sensitivity analyses). In assessing whether poor quality of 
care is associated with the survey characteristics, our tests 
showed weak correlations between poor malaria care 
quality and gross domestic product (GDP) per capita 
(correlation=−0.010), per cent of febrile children out 
of the total population of children under five (correla-
tion=−0.361) and year of survey (correlation=0.209).
Quality of malaria care by treatment cascade
When comparing quality of malaria care by treatment 
cascade (malaria testing, treatment and treatment timeli-
ness), we found that: First, a mean of 62% of febrile chil-
dren were reported not to have any blood test for fever. 
The highest percentages of children who did not have a 
blood test were in Cambodia (93%, n=985), Zimbabwe 
(83%, n=401) and Nigeria (82%, n=1807). The lowest 
percentages without a blood test were in Liberia (32%, 
n=813), Zambia (41%, n=996) and Sierra Leone (43%, 
n=638). We found no available information on blood 
testing in Cameroon, Ethiopia, Senegal and Swaziland. 
Second, for antimalarial use, a mean of 82% of febrile 
children who sought care reported that they did not 
receive any treatment drug and 17% reported receiving 
one antimalarial drug. Specifically, all but one case in 
Cambodia reporting not having any antimalarial treat-
ment (100%), while Tanzania had the lowest record for 
no treatment at 44%. For inadequate treatment, 56% 
of cases in Tanzania were treated with one antimalarial 
drug, while Cambodia had one case treated with one anti-
malarial drug. Third, for treatment timeliness, a mean 
of 72% of febrile children with treatment encounter 
received care after 24 hours from onset of fever. Of those 
who received delayed treatment, 15% received care 
after 3 days, the longest delay recorded was in 9 days. All 
treated cases in Cambodia, Ethiopia, Mozambique and 
Swaziland received delayed treatment, while the lowest 
recorded was half of all treated cases in Burundi and 
Zimbabwe (figure 2 and table 2).
Quality of malaria care by regions
Quality of malaria care varies by 11% to 30% when 
comparing across regions of each study country (figure 3, 
Appendices 8 and 9). The highest regional difference 
of 30% in quality of malaria care was in Tanzania. In 
Tanzania, the highest percentages of patient encounters 
with problems on malaria care quality were in Simiyu 
(81%, n=216), Shinyanga (77%, n=167) and Mara (76%, 
n=252), while the lowest were in Zanzibar North (52%), 
Dar es salaam (55%) and Pwani (55%). Across the study 
countries, the lowest regional percentages estimated 
were in Ghana: Upper East (41%, n=136), Upper West 
(45%, n=100) and Brong Ahafo (46%, n=154).
dIsCussIon
Across the 25 study countries, we found that 58% (48% 
to 68%) of patient encounters of children under 5 years 
of age with suspected malaria met the criteria for poor 
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Figure 2 Percent of cases among febrile children under 
five by malaria treatment cascade defined as: reported not 
receiving any drug treatment, reported being treated after 
24 hours, reported not receiving any blood test, or reported 
being treated with one antimalarial drug. All percentages 
were calculated as number of febrile children under five out 
of all reported patient encounters.
quality care. Specifically, we noted that only about two 
out of five patients were blood tested prior to treatment 
as recommended by the universal ‘test and treat’ WHO 
strategy for malaria. Consequently, in about four out of 
five patient encounters, a child was treated with inappro-
priate antimalarial drugs and more than half had delayed 
treatment. We also found large variations in quality 
of malaria care across countries and regions. Taken 
together, quality of malaria care remains poor in many 
malaria- endemic LMICs and widely varies by treatment 
cascade and geography, suggesting that increasing access 
to care alone may not be sufficient to reduce malaria 
mortality rates.
When care is accessible, we found that children often 
receive inappropriate care. This variation ranges from 
diagnostics to therapies. It is true that WHO used to 
suggest presumptive treatment but given the rise of inef-
fective and wasteful use of antimalarial drugs,14 WHO’s 
approach has become more cautious. Globally, invest-
ments for mRDTs alone is as high as US$213 million last 
year, but its use in malaria care is perceived as unreliable 
especially in high transmission areas.17 In high transmis-
sion areas, parasitological diagnosis was argued to have 
lower specificity and the cost of testing may be higher 
than the cost of treatment.17 Thus, this lack of adherence 
or compliance to testing requirements may be driven not 
just by the lack of availability of diagnostic tests, but also by 
providers’ perceptions that the benefits of treating based 
on clinical symptoms rather than test results outweigh the 
risks.18 19 Previous studies noted that RDTs also remain 
positive for a highly variable amount of time after treat-
ment with antimalarials (up to 60 days after treatment), 
and the duration of positivity is highly dependent on the 
type of RDT used for diagnosis.20 Further, the quality of 
RDTs was found to be affected by regular exposure to 
temperatures above recommended limits, underlining 
the need to also revisit current global standards on trans-
port and storage of such medical commodities.21 These 
are important issues policymakers need to further tackle.
We found important gaps in treatment practices as 
well—with about two out of three malaria cases being 
incorrectly managed, much of it due to substantial delays 
in treatment. Evidence so far shows that this may be 
due to inadequate guideline emphasis22 or simply lack 
of knowledge among providers regarding malaria case 
management.23 In our study countries, we found that 
undertreatment (26%), specifically monotherapy, was 
higher than overtreatment (9%) of malaria cases, but 
both lead to unnecessary wastes in the health system. If 
undertreated, uncomplicated malaria cases can prog-
ress rapidly to fatal malaria.14 If overtreated, subjecting 
patients to unnecessary antimalarial drugs or improper 
combination of them only increase costs to health systems 
and put more peoples’ lives at risk of antibiotic resistance. 
Of those who were overtreated, 13% of children were also 
found to receive an antimalarial drug even with a negative 
malaria test result. Inappropriate treatment practices are 
further exacerbated by delays in treatment that can be 
caused by both access and quality issues, recorded to be 
as delayed as 9 days from the onset of fever in some study 
countries. In Burkina Faso, treatment delays were found 
to be due to the patient’s capacity to afford the cost of 
care.24 Some studies have found that integrated commu-
nity case management using home- based care and aboli-
tion of user fees may reduce treatment delays.24 25
Designing an intervention to reduce poor malaria care 
quality is beyond the scope of this study, but these find-
ings quantifying the degree and location in the treatment 
cascade of poor malaria care quality provide evidence 
for increased attention on malaria quality of care. Thus, 
malaria strategies should include interventions to address 
quality of care. Generally, malaria resource allocation is 
based on malaria endemicity, wherein more resources for 
malaria testing and treatment are targeted in high trans-
mission areas. However, our additional analyses showed 
that malaria endemicity as a proxy for resource allocation 
was not correlated with quality of care (correlation=−0.01, 
online supplementary appendix). Thus, such resource 
allocation may not necessarily be translated to better 
quality of malaria care, suggesting that increasing diag-
nostic tools and antimalarial drugs alone are not enough.
At the regional level, estimating disparities on malaria 
care quality provides a more detailed picture of the 
hotspots of poor malaria care (online supplementary 
appendix 8 and 9). Our findings in Uganda showing 
60% poor malaria care quality are reflective of previous 
findings that adherence to Ugandan national malaria 
treatment guidelines was only at 50.6% in 2016,26 with 
about 15% of providers not knowing the first- line treat-
ment for uncomplicated malaria.27 Similarly, being in the 
capitals of these countries does not translate to better 
quality of malaria care as supported by previous litera-
ture.28 Regional disparities in malaria care quality may 
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Table 2 Problems with malaria care quality among febrile under five children in 25 LMICs by treatment cascade
Country
Not blood 
tested*
Not treated with any 
drug†
Treated with only one 
malarial drug†
Receipt of treatment 
after 24 hours‡
N % N % N % N %
Tanzania (n=1413) 1035 73% 614 44% 781 56% 476 61%
Nigeria (n=2213) 1807 82% 1465 69% 623 29% 425 63%
Mozambique (n=1018) 496 49% 563 56% 434 43% 435 100%
Mali (n=1655) 1363 82% 1193 75% 366 23% 283 71%
Cambodia (n=1062) 985 93% 1060 100% 1 0% 1 100%
Burkina Faso (n=2200) 1367 62% 1240 57% 903 41% 609 65%
Madagascar (n=899) 726 81% 818 91% 79 9% 64 79%
Togo (n=708) 453 64% 476 68% 224 32% 149 66%
Zimbabwe (n=486) 401 83% 477 98% 6 1% 4 50%
Angola (n=912) 516 57% 627 70% 264 30% 213 81%
Namibia (n=433) 332 77% 417 96% 13 3% 13 81%
Malawi (n=1082) 554 51% 754 71% 310 29% 174 56%
Cameroon (n=1204) 901 76% 283 24% 198 69%
Ethiopia (n=624) 532 86% 83 13% 85 100%
Uganda (n=1329) 822 62% 1184 89% 108 8% 81 56%
Rwanda (n=659) 400 61% 619 94% 37 6% 29 78%
Gambia (n=371) 221 60% 354 96% 14 4% 8 57%
Ghana (n=830) 418 50% 498 60% 172 21% 197 60%
Kenya (n=1146) 654 57% 1114 97% 25 2% 18 58%
Burundi (n=1068) 514 48% 930 87% 127 12% 69 50%
Swaziland (n=586) 582 99% 4 1% 4 100%
Senegal (n=2926) 2690 92% 167 6% 182 81%
Zambia (n=2411) 996 41% 2299 95% 107 4% 87 78%
Sierra Leone (n=1495) 638 43% 1405 94% 68 5% 54 64%
Liberia (n=944) 298 32% 813 87% 108 12% 91 72%
Total (n=29 674) 14 996 23 625 5307 3949
Mean 62% 82% 17% 72%
There is no available information on blood testing in Cameroon, Ethiopia, Senegal and Swaziland. All data were analysed using survey 
weights.
*Among those with fever reported in the last 2 weeks.
†Among those with fever reported in the last 2 weeks and had a treatment encounter.
‡Among those with fever reported in the last 2 weeks and were treated with any malarial drug.
LMICs, low- income and middle- income countries.
be driven by socioeconomic and regional characteristics 
(eg, funding, governance, human resource availability) 
which can be explored once data become available.
Our findings were consistent with previous studies that 
were mostly conducted in a subset of countries or regions. 
For malaria testing, a 2017 study in five sub- Saharan 
African countries found that an average of 87% of patients 
without a blood test had antimalarial drugs.29 Our find-
ings expanding the scope to 25 study countries showed a 
decline to 62% that were not blood tested. Although this 
may show some improvements in blood testing, more work 
still needs to be done in ensuring adherence to testing 
requirements. In treating malaria, compliance with the 
recommended first- line medication for uncomplicated 
malaria was also found to be low in many country- level 
studies.30 31 A cross- country study showed that less than a 
third of fevers were treated according to the national guide-
lines and only about 40% on fevers on average (ranging 
from 8% to 72%) were managed effectively.32 By expanding 
this previous cross- country study using more updated data, 
our findings showed similarly huge variations in care across 
countries (48% to 69%) and across regions (11% to 30%). 
Further, instead of simply aggregating poor quality of care 
in a summative measure, we were able to disentangle where 
quality of care was worse, highlighting the bottlenecks and 
system failures that need stronger quality improvement 
measures.
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Figure 3 Quality of malaria care by region with 0 as lowest 
performing to 1 as highest performing region. In grey are 
areas not included in the study due to data availability or 
incomplete/missing information.
We also found that existing nationally representative 
malaria surveys still do not comprehensively capture 
malaria care quality, as discussed in our data gap anal-
ysis. We also noted patient encounters wherein only one 
antimalarial drug or more than three antimalarial drugs 
were given to a febrile child. Such data could have been 
improved if we were able to identify which antimalarial 
drug may have actually been given to the child during 
the treatment process. Consequently, the calculations for 
poor malaria care quality may be an overestimation given 
that we were not able to restrict our analysis based on test 
results and antimalarial drugs for all the 25 study coun-
tries. Nevertheless, the four study countries that had addi-
tional laboratory- confirmed malaria test results showed 
that treatment prescriptions were provided regardless of 
the test results (35% of cases, see online supplementary 
appendix). The findings also do not vary as much when 
using different estimation methods (online supplemen-
tary appendix). Thus, although we were limited by the 
availability of data that could have influenced the accu-
racy of the estimations, our findings provide evidence 
that poor malaria care quality occurs in large percentages 
in these malaria- endemic LMICs. Although we found 
weak correlations between quality of malaria care and 
survey characteristics (survey year, GDP per capita, per 
cent of febrile children), the estimations may have been 
reflective of the existing policies of the countries at the 
time of the survey; thus, this may not necessarily point 
to lack of accountability of the governments and the 
providers. Nevertheless, our findings showed that malaria 
care quality at that time is still poor in comparison to 
existing guidelines, providing evidence about the need to 
focus on strengthening implementation of malaria care 
policies in these countries. Future research will update 
our estimations and track progress on malaria care once 
more recent survey data become available, including any 
data on comorbidities of the febrile children. Although 
we noted weak correlations of GDP per capita and survey 
year on the estimations of poor malaria care quality, 
future research may further explore how other factors 
such as war, poverty and lack of qualified healthcare 
professionals may affect the quality of care, not only for 
malaria care, but generally across different populations. 
Since full implementation does not occur immediately 
after releasing a global guideline, future studies may also 
collect data on when each country has fully implemented 
the WHO guideline to assess changes in quality of malaria 
care pre- implementation and post- implementation.
ConClusIon
In summary, malaria care quality remains poor across 
the 25 study countries with over half of patient encoun-
ters reportedly having poor malaria care quality. Quanti-
fying the burden of poor malaria care quality is crucial, 
particularly at a time when global investment for malaria 
has plateaued and progress has stalled.33 Our findings 
provided evidence that the WHO recommendation for 
all cases of suspected malaria to have a parasitological test 
before prescribing treatment is not being widely prac-
ticed. Although availability of mRDTs and antimalarial 
drugs are critical, ensuring adherence to quality malaria 
care is equally important.27 34 35 Unless quality of malaria 
care is improved, malaria will continue to be one of the 
five leading causes of under- five mortality and the global 
goal of reducing malaria mortality rates by at least 90% by 
2030 will remain unattainable for many LMICs.
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